gp130 receptor ligands as potential therapeutic targets for obesity.
about
AdipogenesisHuman IL6 enhances leptin action in mice.Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130.Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome.Common genetic variation in the human CTF1 locus, encoding cardiotrophin-1, determines insulin sensitivity.Hypothalamic mechanisms in cachexia.Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance.Forum on bone and skeletal muscle interactions: summary of the proceedings of an ASBMR workshop.Gp130 cytokines exert differential patterns of crosstalk in adipocytes both in vitro and in vivo.The gp130 receptor cytokine family: regulators of adipocyte development and function.Amylin-induced central IL-6 production enhances ventromedial hypothalamic leptin signaling.IL-17 in obesity and adipogenesis.Cardiotrophin-1 is inversely associated with obesity in non-diabetic individuals.Inflammatory mechanisms in the regulation of insulin resistance.Developmental changes of leptin receptors in cerebral microvessels: unexpected relation to leptin transport.Neuropoietin attenuates adipogenesis and induces insulin resistance in adipocytes.Update on the pathophysiological activities of the cardiac molecule cardiotrophin-1 in obesity.The role of interleukin-6 in insulin resistance, body fat distribution and energy balance.Interleukin-18 activates skeletal muscle AMPK and reduces weight gain and insulin resistance in miceCiliary neurotrophic factor stimulates muscle glucose uptake by a PI3-kinase-dependent pathway that is impaired with obesity.Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expressionCardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography.Bile acid-induced inflammatory signaling in mice lacking Foxa2 in the liver leads to activation of mTOR and age-onset obesity.Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia.Oncostatin m is produced in adipose tissue and is regulated in conditions of obesity and type 2 diabetes.Targeting gp130 to prevent inflammation and promote insulin action.gp130: a promising drug target for cancer therapy.Cardiotrophin-1 stimulates lipolysis through the regulation of main adipose tissue lipases.Oncostatin m modulation of lipid storage.Cardiotrophin-1: a new player in energy metabolism with potential therapeutic application.Hypothalamic Insulin Resistance in Obesity: Effects on Glucose Homeostasis.Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options.The ever-expanding myokinome: discovery challenges and therapeutic implications.Role of cardiotrophin-1 in obesity and insulin resistanceLoss of Oncostatin M Signaling in Adipocytes Induces Insulin Resistance and Adipose Tissue Inflammation in Vivo.Cardiotrophin-1 Regulates Adipokine Production in 3T3-L1 Adipocytes and Adipose Tissue From Obese Mice.PAP/HIP protein is an obesogenic factor.Anti-obesity effects of granulocyte-colony stimulating factor in Otsuka-Long-Evans-Tokushima fatty rats.Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice.Obesity predisposes to Th17 bias.
P2860
Q26828614-53801F2A-2676-42EF-85AA-46BFDD967280Q33628094-9ABF9DA4-4BD2-4299-AA69-1888A351CDD5Q33634360-4CD55BA7-89BA-4604-9E6E-B9B92DBCF482Q33750620-8E6E0754-1E41-42F8-ABEE-32F8B85D5AE1Q33904645-467B3134-D9B3-47BA-956E-9CB3DFFEAA49Q34081332-31D38956-2F28-4EE4-8F95-23C5CB831A6BQ34238563-6419FA58-2944-4CBB-8FD5-A7A0A18A81F8Q34344489-21B0865B-4A4E-45B4-A419-F762FAF79B20Q34827533-58545A26-F8A7-4281-ABD2-35A04BABF8D8Q35059389-99C9FDB6-1032-40A7-9FF3-7D541A010A51Q35532268-FE16BB1F-A799-49B8-A219-398081C23508Q35676503-F28E7696-9E6F-44F7-AE2D-A0611747BCE0Q36333479-CEFB0A93-85E7-415A-BB72-441A1B51F6E4Q36409227-F62CFB15-EB51-48DA-9C0E-B1D2D616C025Q36513381-48EA59F5-5283-46D3-8FA8-9C183F79BBBEQ36825535-46AAB5ED-553D-4C72-8B5C-C07F9051FD64Q36830891-DA6932EF-67B2-4BD7-BFDD-4BE484E38C8CQ36979956-D81CEFA0-36FD-49EF-AC47-791A1C74D775Q37110553-64801F28-6300-4BA4-AB27-A9771594F778Q37141767-BD0A259B-000C-4D22-A8F3-8CDAAEB82408Q37163458-4587ACAC-31BB-4891-A86D-565306BEA1ABQ37180152-E1F8E7F9-4F17-455F-A2CB-5DCDDA468A5CQ37373147-AFC4D7B3-1271-4443-9959-FBD1C620C3D9Q37503704-C0A8C296-25B0-4044-8E06-75F884B5DE6FQ37554810-0577294E-C8C0-4E54-BD60-9F64B9E63F8DQ38134113-7BAB6CB2-29C9-42AA-8C2B-85DED4B703F8Q38149939-90F67B55-9027-42FF-9145-B7053D3237CBQ38303328-47568F4B-826C-4FBC-B731-CD209EE407EDQ38358416-349100DA-C414-478B-88AA-50A9ED03C102Q38608382-D1A21792-1665-47B5-8F9F-A1C2D9ADB179Q38765909-CC3C60D7-ED27-498D-9985-490AF7CD71F1Q38818675-D49C41A2-EC83-4CFB-8168-61E70CCAB785Q38951385-5D718863-9EE6-4C0F-86BC-1D5F981830B7Q39331776-E2417128-132F-4498-AD9E-0FE0A88D315FQ41045705-CBEFAB75-AD85-4E26-90B6-2EF48131D84AQ42807485-EA7FF123-3209-4D58-AC94-D610336C2646Q42816086-CFD29460-A115-4EE7-8AAF-58ADE35E4E30Q42829773-262F7A88-0071-41EC-9B6C-2E7D526C4DD4Q43109145-DF34FC04-8778-4DB1-84C5-5F9169BDE695Q43296795-30BF6F8D-2862-483E-9A5F-BE7C1A9204FF
P2860
gp130 receptor ligands as potential therapeutic targets for obesity.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
gp130 receptor ligands as potential therapeutic targets for obesity.
@ast
gp130 receptor ligands as potential therapeutic targets for obesity.
@en
type
label
gp130 receptor ligands as potential therapeutic targets for obesity.
@ast
gp130 receptor ligands as potential therapeutic targets for obesity.
@en
prefLabel
gp130 receptor ligands as potential therapeutic targets for obesity.
@ast
gp130 receptor ligands as potential therapeutic targets for obesity.
@en
P2860
P356
P1476
gp130 receptor ligands as potential therapeutic targets for obesity.
@en
P2093
Mark A Febbraio
P2860
P304
P356
10.1172/JCI30453
P407
P577
2007-04-01T00:00:00Z